STOCK TITAN
  1. Home
  2. Sec-filings
  3. BTAI
  4. [Form 4] BioXcel Therapeutics, Inc. Insider Trading Activity

BioXcel (BTAI) CFO gains 35 shares as 212 RSUs remain

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised derivative awards tied to company equity. On June 15, 2026, he acquired 35 shares of Common Stock upon conversion of Restricted Stock Units, bringing his direct Common Stock holdings to 26,335 shares. Following the transaction, he also directly held 212 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock under a vesting schedule from a March 15, 2023 grant of 562 RSUs.

Positive

  • None.

Negative

  • None.
Insider Steinhart Richard I
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 35 $0.00 --
Exercise Common Stock 35 $0.00 --
Holdings After Transaction: Restricted Stock Units — 212 shares (Direct, null); Common Stock — 26,335 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Shares acquired 35 shares Common Stock acquired on June 15, 2026 via RSU exercise
Shares held after 26,335 shares Direct Common Stock holdings following the transaction
RSUs remaining 212 RSUs Direct Restricted Stock Unit holdings after the transaction
Original RSU grant 562 RSUs Granted on March 15, 2023
Initial vesting tranche 25% Vests on first anniversary of March 15, 2023
Quarterly vesting rate 6.25% Vests at end of each successive three-month period thereafter
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
vesting financial
"562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Financial Officer financial
"Steinhart Richard I … officer_title: "Chief Financial Officer""
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Steinhart Richard I
(Last)(First)(Middle)
C/O BIOXCEL THERAPEUTICS, INC.
555 LONG WHARF DRIVE, 12TH FLOOR
(Street)
NEW HAVEN CONNECTICUT 06511
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026M35A(1)26,335D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/15/2026M35 (2) (2)Common Stock35$0212D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
/s/ Richard Steinhart06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BioXcel Therapeutics (BTAI) report for its CFO?

BioXcel Therapeutics reported that CFO Richard I. Steinhart acquired 35 shares of Common Stock through the exercise of Restricted Stock Units on June 15, 2026. This action converts previously granted RSUs into actual shares under his equity compensation plan.

How many BioXcel (BTAI) shares does the CFO hold after this Form 4?

After the June 15, 2026 transaction, CFO Richard I. Steinhart directly holds 26,335 shares of BioXcel Therapeutics Common Stock. This reflects the addition of 35 shares acquired through the exercise of Restricted Stock Units disclosed in the filing.

What Restricted Stock Unit position remains for the BioXcel (BTAI) CFO?

Following the reported transaction, the CFO directly holds 212 Restricted Stock Units. Each RSU represents a contingent right to receive one share of BioXcel Therapeutics Common Stock, subject to the original vesting conditions described in the grant documentation.

What was the original RSU grant reported for the BioXcel (BTAI) CFO?

On March 15, 2023, the CFO was granted 562 Restricted Stock Units. Twenty-five percent vest on the first anniversary of March 15, 2023, and 6.25% vest at the end of each successive three‑month period, subject to his continuous employment with BioXcel Therapeutics.

How do the BioXcel (BTAI) CFO’s RSUs convert into Common Stock?

Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. As RSUs vest under the specified schedule and conditions, they can be settled in shares, as shown by the 35 RSUs converted into 35 Common shares on June 15, 2026.